SynthesisJournal of clinical pharmacology2025
Saliva as a TDM Matrix and Its Application in the Model-Informed Precision Dosing.
Synthesis in Journal of clinical pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- From Data to Dose: Diversity in Therapeutic Drug Monitoring and Pharmacokinetics-Based Individualization of Drug Therapy.Pharmaceutics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study reviews the main points of saliva as a therapeutic drug monitoring (TDM) matrix, its advantages and limitations, the methods of saliva sample collection and testing, the types of drugs in saliva TDM, and the methods of establishing saliva population pharmacokinetic (Pop PK) models, as well as summarizes the experiences and limitations, to provide references to carry out related studies. The PubMed database was systematically searched for studies on the topic of saliva as a matrix for drug TDM. The literature was screened according to the established inclusion and exclusion criteria, and relevant data were extracted and summarized. The systematic review ultimately screened 112 articles involving relevant studies on 73 drugs, of which studies on 53 drugs supported saliva as a matrix for TDM; studies on 13 drugs did not support it; and the results of studies on seven drugs were inconsistent, with conflicting results regarding whether they supported salivary TDM or not. The study steps for Pop PK modeling based on saliva concentrations are summarized, and representative drugs for which Pop PK models incorporating both plasma and saliva concentrations have been established are listed. Saliva TDM, as a new exploration and attempt, has been confirmed to be feasible for some drugs in the current study, and is expected to be applied to the clinic in the future; Pop PK modeling based on saliva TDM for precision drug delivery has only been initially attempted for some drugs, and its application has yet to be verified in clinical studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.